<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03907423</url>
  </required_header>
  <id_info>
    <org_study_id>Rosuvastatin on diabetics</org_study_id>
    <nct_id>NCT03907423</nct_id>
  </id_info>
  <brief_title>Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin</brief_title>
  <official_title>Effects of Rosuvastatin on Markers of Atherosclerosis in Diabetic Patients Treated With Glimepiride/Metformin Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      study effects of rosuvastatin on markers of atherosclerosis, thrombosis, in diabetic patients
      treated with glimepiride/metformin without coronary artery disease.

      This effect will be investigated especially on sortilin ,fetuin-A
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized controlled trial on 60 patients with DM type 2 will be recruited from Damanhour
      national medical institute.

        -  Subjects will be divided into two group (one arm is DM-type 2 patients who will receive
           rosuvastatin -metformin-glimepiride combination (40 patients) and another arm is DM-type
           2 patient who will receive glimepiride-metformin combination (20 patients).

        -  Determination of serum levels of fetuin A and Sortilin

        -  Blood samples will be collected after 3-month after active treatment.

        -  Outcomes measurement : Sortilin ,fetuinA, Atherogenic index (AI) and coronary risk index
           (CRI) .

      Methodology

        -  Sortilin, fetuinA will be determined by ELISA.

        -  Lipid profile.

        -  FBG and Hb A1C will be measured.

        -  Atherogenic index (AI = LDL-C/HDL-C) and CRI (CRI = TC/HDL-C) will be calculated for all
           subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be divided into two group (one arm is DM-type 2 patients who will receive rosuvastatin -metformin-glimepiride combination (40 patients) and another arm is DM-type 2 patient who will receive glimepiride-metformin combination (20 patients).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum levels of fetuin A</measure>
    <time_frame>three months</time_frame>
    <description>Fetuin-A has a diagnostic potential as a biomarker for liver dysfunction, cardiovascular diseases and disorders associated with metabolic syndrome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum levels of Sortilin</measure>
    <time_frame>three months</time_frame>
    <description>Sortilin is involved in lipid metabolism, promotes the development of atherosclerosis, and possibly becomes a potential therapeutic target for atherosclerosis treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DM-type 2 patients who will receive rosuvastatin -metformin-glimepiride combination (40 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DM-type 2 patient who will receive glimepiride-metformin combination (20 patients).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin10 mg tablet</intervention_name>
    <description>Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus on oral therapy.

          -  Age 21-65 years

          -  Life expectancy &gt;1 year.

          -  Normal lipid profile

        Exclusion Criteria:

          -  Documented CVD

          -  Planned surgical intervention.

          -  Hypersensitivity to either of the study drug components.

          -  Type I diabetes.

          -  Current Insulin treatment.

          -  Hepatic impairment known hepatic failure.

          -  Inability to comply with study protocol.

          -  Active malignancy.

          -  Chronic inflammation (i.e. inflammatory bowel disease, lupus, inflammatory arthritis,
             rheumatoid arthritis) or chronic infection (i.e. chronic diabetic foot infection).

          -  Pregnancy, lactation or child-bearing potential.

          -  Chronic renal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rehab H Werida, Lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Damanhour University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ola M Elattar, Bachelor</last_name>
    <phone>01110085281</phone>
    <email>Phelattar90@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Damanhour Medical National Institute</name>
      <address>
        <city>Damanhūr</city>
        <state>N/A = Not Appُlicable</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reem Abd-el-ghafour, Ph.D,</last_name>
      <email>reemdoc10@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Oh TJ, Ahn CH, Kim BR, Kim KM, Moon JH, Lim S, Park KS, Lim C, Jang H, Choi SH. Circulating sortilin level as a potential biomarker for coronary atherosclerosis and diabetes mellitus. Cardiovasc Diabetol. 2017 Jul 20;16(1):92. doi: 10.1186/s12933-017-0568-9.</citation>
    <PMID>28728579</PMID>
  </reference>
  <reference>
    <citation>Dabrowska AM, Tarach JS, Wojtysiak-Duma B, Duma D. Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Sep;159(3):352-9. doi: 10.5507/bp.2015.018. Epub 2015 Apr 24. Review.</citation>
    <PMID>25916279</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>April 14, 2019</last_update_submitted>
  <last_update_submitted_qc>April 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

